{"entity":{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","aka":[],"tldr":"Using two HER2 antibodies (trastuzumab and pertuzumab) at once, which works better than one.","summary":"Trastuzumab (domain IV) plus pertuzumab (domain II) block ligand-independent and ligand-dependent signalling and enhance ADCC. CLEOPATRA (OS +16 months), NeoSphere (pCR), and APHINITY (node-positive iDFS) established it; Phesgo delivers both subcutaneously. Now being paired with T-DXd (DESTINY-Breast09) and tucatinib (HER2CLIMB-05).","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Pertuzumab","links":[{"label":"ClinicalTrials.gov NCT00567190: CLEOPATRA","url":"https://clinicaltrials.gov/study/NCT00567190"},{"label":"ClinicalTrials.gov NCT01358877: APHINITY","url":"https://clinicaltrials.gov/study/NCT01358877"}],"tags":[],"related":["pet-adapted-her2-deescalation"],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":["her2","her3"],"drugs":["trastuzumab","pertuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cleopatra","aphinity"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Treatment jargon"},"route":"/terms/dual-her2-blockade/","neighbours":{"pairing":[{"id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/"}],"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"trial":[{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/"},{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/"}],"biomarker":[{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/"}]}}